share_log

HC Wainwright & Co. Reiterates Buy on Acrivon Therapeutics, Maintains $20 Price Target

HC Wainwright & Co. Reiterates Buy on Acrivon Therapeutics, Maintains $20 Price Target

HC Wainwright & Co.重申买入Acrivon Therapeutics,维持20美元的目标股价
Benzinga ·  04/25 07:29

HC Wainwright & Co. analyst Emily Bodnar reiterates Acrivon Therapeutics (NASDAQ:ACRV) with a Buy and maintains $20 price target.

HC Wainwright & Co. 分析师艾米丽·博德纳尔重申Acrivon Therapeutics(纳斯达克股票代码:ACRV)的买入并维持20美元的目标股价。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发